)
Visual
earnings real time
Takeda Pharmaceutical Company
Takeda Pharmaceutical Company (4502) investor relations material
Takeda Pharmaceutical Company Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary29 Jan, 2026
Executive summary
Revenue for the nine-month period ended December 31, 2025, was JPY 3,411.2 billion, down 3.3% year-over-year, mainly due to Vyvanse generic erosion and Neuroscience headwinds, partially offset by growth in launch products.
Core operating profit declined 3.4% year-over-year to JPY 971.6 billion, but reported operating profit rose 1.2% to JPY 422.4 billion due to lower restructuring costs offsetting impairment charges.
Net profit attributable to owners was JPY 216.1 billion, up 2.4% year-over-year, with EPS at 137 yen (+2.7%).
Adjusted free cash flow increased 10.1% year-over-year to JPY 625.9 billion, reflecting improved working capital and higher operating cash flow.
Leadership transition to Julie Kim as CEO is underway to ensure continuity and momentum for upcoming launches.
Financial highlights
Revenue: JPY 3,411.2 billion (−3.3% year-over-year, −2.8% at CER); core operating profit: JPY 971.6 billion (−3.4% year-over-year); reported operating profit: JPY 422.4 billion (+1.2% year-over-year).
Net profit: JPY 216.1 billion (+2.4% year-over-year); EPS: 137 yen (+2.7% year-over-year); core EPS: JPY 428.
Adjusted free cash flow: JPY 625.9 billion (+10.1% year-over-year), even after $1.2 billion upfront payment to Innovent Biologics.
Operating cash flow: JPY 966.9 billion (+15.8% year-over-year); cash and cash equivalents at period end: JPY 654.9 billion.
Gross margin stable at 65.8% for the period.
Outlook and guidance
FY2025 revenue forecast revised up to JPY 4,530.0 billion, with core operating profit forecast at JPY 1,150.0 billion and core EPS at JPY 486.
Adjusted free cash flow guidance increased to JPY 650.0–750.0 billion.
Annual dividend per share maintained at JPY 200.
Continued OpEx discipline expected to offset gross profit impact from Vyvanse and FX volatility.
Management guidance at CER projects low-single-digit declines in core revenue, core operating profit, and core EPS.
How do growth products mitigate VYVANSE erosion?
Detail the gamma delta T-cell therapy impairment.
Explain the revised low-teen cash tax rate.
New product profit contribution timing by asset?
ENTYVIO biosimilar strategy post-IRA selection?
Org changes: AI/tech impact on launch execution?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- EMCURE
Q3FY26 revenue rose 20% YoY, PAT up 48%, with margin gains and robust global growth. - 500870
Record revenue and 8% volume growth in FY25, with robust margins and strong dividend payout. - SOI
Q3 revenue €160m, up 18% sequentially, Edge & Cloud AI up 27%, Q4 set for 20% growth. - IFX
Q1 2026 revenue rose 7% year-over-year, driven by AI demand and increased investments. - ELS
2025 revenue soared 11x to $23M, with strong cash, major contracts, and a robust 2026 outlook. - V2RETAIL
Q3 FY26 saw 57% revenue and 99% PAT growth, with robust expansion and capital infusion. - UBSG
Net profit surged 53% in FY25, with integration and cost savings driving strong results. - 524348
Q3 FY26 revenue up 8% and PAT up 58%, with margin recovery and new projects ramping up. - BOTX
Record gold output and profit, with investments driving strong growth outlook for 2026. - BAJAJFINSV
Q3 FY26 profit was flat at ₹2,229 crore as strong growth was offset by one-time charges.
Next Takeda Pharmaceutical Company earnings date
Q4 20267 May, 2026
Takeda Pharmaceutical Company
Next Takeda Pharmaceutical Company earnings date
Q4 20267 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Takeda Pharmaceutical Company Limited, founded in 1781, is a research-based global company. The Company's segment is engaged in the research and development, manufacturing and marketing of pharmaceutical products. Through its global presence in over 70 countries, the Company offers a range of products to meet unmet medical needs in a variety of therapeutic areas, including gastroenterology, oncology and neuroscience, among others. The Company's business unit includes Gastroenterology Business Unit, Oncology Business Unit and General Medicines Business Unit. GBU's focus is on creating new value in GI diseases to enhance the lives of patients and their families. OBU's focus is on building a portfolio with the potential to serve patients worldwide that address unmet cancers. GMBU focuses on providing innovative treatment options for patients in such disease areas as internal medicine, respiratory, renal and central nervous system.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage